Skip to Content

Sogroya FDA Approval History

Last updated by Judith Stewart, BPharm on Sep 3, 2020.

FDA Approved: Yes (First approved August 28, 2020)
Brand name: Sogroya
Generic name: somapacitan-beco
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Adult Human Growth Hormone Deficiency

Sogroya (somapacitan-beco) is a human growth hormone analog indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

  • Sogroya is administered by subcutaneous injection into the abdomen or thigh one time each week.
  • Common side effects (≥2%) include back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia.

Development Timeline for Sogroya

DateArticle
Aug 28, 2020Approval  FDA Approves Sogroya (somapacitan-beco) a Once-Weekly Treatment for Adult Growth Hormone Deficiency

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.